Your browser doesn't support javascript.
loading
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
Frezza, Anna Maria; Beale, Tim; Bomanji, Jamshed; Jay, Amrita; Kalavrezos, Nicholas; Dileo, Palma; Whelan, Jeremy; Strauss, Sandra J.
Affiliation
  • Strauss SJ; The London Sarcoma Service, University College London Hospital, London, England. s.strauss@ucl.ac.uk.
BMC Cancer ; 14: 23, 2014 Jan 15.
Article in En | MEDLINE | ID: mdl-24422949

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skull / Bone Neoplasms / Osteosarcoma / Radiopharmaceuticals / Fluorodeoxyglucose F18 / Neoadjuvant Therapy / Facial Bones Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2014 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skull / Bone Neoplasms / Osteosarcoma / Radiopharmaceuticals / Fluorodeoxyglucose F18 / Neoadjuvant Therapy / Facial Bones Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2014 Type: Article